Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells

Fig. 6

Levels of CD80/CD86 on the surface of the memory B cells correlate with disease severity in the RA patients. a Surface level of CD80 or CD86 on peripheral blood memory B cells of RA patients during abatacept treatment was monitored for 4 months (n = 18). PBMCs from the RA patients were stained with anti-CD20 and anti-CD27 antibodies in the presence of anti-CD80 or anti-CD86 antibodies. The analysis of CD80 or CD86 level was gated on memory (CD20+CD27+) cells. The surface level (ΔMFI) was calculated as the mean fluorescence intensity level of CD80/CD86 minus the isotype control. b Comparison of the responses of the RA patients with or without decreased CD80 or CD86 levels on the surface of the memory B cells. EULAR, European League Against Rheumatism collaborative initiative classification criteria. The patients were classified as good responders, moderate responders, and non-responders according to the DAS28-ESR levels and their improvement from the baseline 6 months after abatacept treatment

Back to article page
\